Format

Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2002 Feb 28;346(9):645-52.

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Author information

1
M.D. Anderson Cancer Center, Houston, TX 77030, USA. hkantarj@mdanderson.org

Erratum in

  • N Engl J Med 2002 Jun 13;346(24):1923.

Abstract

BACKGROUND:

Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase.

METHODS:

A total of 532 patients with late--chronic-phase CML in whom previous therapy with interferon alfa had failed were treated with 400 mg of oral imatinib daily. Patients were evaluated for cytogenetic and hematologic responses. Time to progression, survival, and toxic effects were also evaluated.

RESULTS:

Imatinib induced major cytogenetic responses in 60 percent of the 454 patients with confirmed chronic-phase CML and complete hematologic responses in 95 percent. After a median follow-up of 18 months, CML had not progressed to the accelerated or blast phases in an estimated 89 percent of patients, and 95 percent of the patients were alive. Grade 3 or 4 nonhematologic toxic effects were infrequent, and hematologic toxic effects were manageable. Only 2 percent of patients discontinued treatment because of drug-related adverse events, and no treatment-related deaths occurred.

CONCLUSIONS:

Imatinib induced high rates of cytogenetic and hematologic responses in patients with chronic-phase CML in whom previous interferon therapy had failed.

Comment in

PMID:
11870241
DOI:
10.1056/NEJMoa011573
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center